Revolutionising Cell & Gene Therapy Starts at the Bioreactor
Efficient, Low-Shear Bioprocessing for
Next-Gen Manufacturing
Born in Academia, Built for Industry
Cytovate is a bioprocessing innovation developed at the University of Bath by a team of bioprocess engineers and cell culture specialists.
We have developed a scalable fluidised bed bioreactor that addresses the limitations of traditional stirred tank systems, offering a better solution for high-density cultures of shear-sensitive and novel therapeutic cell types.
Built by Bioprocess Engineers and Cell Culture Experts. Cytovate delivers the next revolution in scalable, gentle biomanufacturing.
Why Current Bioprocess Systems Fall Short
Current bioprocess platforms, especially stirred tank reactors, face key challenges due to increasingly high shear and poor mass transfer as they scale up.
These limitations impact efficiency, cell viability and the feasibility of producing sensitive cell types.
Gentle Yet Powerful: A Smarter Way to Grow Cells
Cytovate’s innovative fluidised bed bioreactor provides a low-shear, high mass transfer environment that enables cells to thrive at higher densities – media requirements and process costs are reduced, while scalability and viability are enhanced.
This is achieved by replacing mechanical agitation with a dynamic flow system, suspending cells gently within a column of upwardly perfused media, enabling up to 10x higher cell densities than stirred tank bioreactors, and enabling the manufacture of sensitive cell types underserved by current technologies.
Consistent Yields, Faster Timelines
Contributing to faster development timelines and lower manufacturing risk.
Efficient Resource Use
Lower media consumption and reduce cost per batch.
Enabling Cost Effective Cell Manufacturing
Grow therapeutic cells that were once too fragile or expensive to scale.
Empowering the Future of Therapeutics
Our technology is designed to meet the needs of key stakeholders across the biomanufacturing ecosystem, from innovation at the bench to scale-up on the production floor.
Designed with these users in mind:
Biotech and Pharma Companies
Academic & Transactional Research Centres
CDMOs, CROs & CRAMs
End Users: Scientists & Manufacturing Teams
The Team Behind the Breakthrough
At the heart of Cytovate is a multidisciplinary team of scientists, engineers and industry experts committed to redefining biomanufacturing.
With deep experience in cell therapy, biologics and process development, our team brings together the insight and innovation needed to drive real impact in therapeutic production.
David Phillips, PhD,
CEO
Sandhya Moise, PhD,
CSO
Katharine Fraser
PhD
Start a Conversation About Smarter Cell Culture
Interested in scaling up your bioprocess, reducing shear stress or exploring how our technology can support your cell therapy or biologics program?
Complete the form and we’ll be in touch to discuss how Cytovate can support your goals in advanced biomanufacturing.